This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2677v1 69/3/896    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, Y. Articles by Han, S. Search for Related Content PubMed PubMed Citation Articles by Zheng, Y. Articles by Han, S.

Prostaglandin E₂ Stimulates Human Lung Carcinoma Cell Growth through Induction of Integrin-Linked Kinase: The Involvement of EP4 and Sp1

¹ Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine; ² Atlanta Veterans Affairs Medical Center, Atlanta, Georgia and ³ Department of Obstetrics and Gynecology, West China 2nd University Hospital, Sichuan University, Chengdu, Sichuan Province, China

Requests for reprints: ShouWei Han, Division of Pulmonary, Allergy and Critical Care Medicine, Emory University School of Medicine, Whitehead Bioresearch Building, 615 Michael Street, Suite 205-M, Atlanta, GA 30322. Phone: 404-712-2661; Fax: 404-712-2151; E-mail: shan2{at}emory.edu.

Key Words: PGE₂ • ILK • EP4 • Sp1 • human lung carcinoma cells

Cyclooxygenase-2–derived prostaglandin E₂ (PGE₂) stimulates tumor cell growth and progression. However, the mechanisms by which PGE₂ increases tumor growth remain incompletely understood. In studies performed in non–small cell lung carcinoma (NSCLC) cells, we found that PGE₂ stimulates the expression of integrin-linked kinase (ILK). ILK small interfering RNA (siRNA) inhibited the mitogenic effects of PGE₂. In view of its perceived importance, we turned our attention to the mechanisms involved in PGE₂-induced ILK expression and found that this effect was blocked by an antagonist of the PGE₂ receptor subtype EP4 and by EP4 siRNA. Furthermore, we showed that PGE₂ induction of ILK was associated with phosphorylation of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt, which were abrogated by ILK siRNA. Transient transfection, gel mobility shift assays, and chromatin immunoprecipitation experiments showed that PGE₂ induced ILK promoter activity and increased Sp1, although it had no effect on nuclear factor-B and AP-2 DNA-binding activity. Blockade of Sp1 abrogated the effect of PGE₂ on expression of ILK and promoter activity and on cell growth. In summary, our observations show that PGE₂ increases NSCLC cell growth through increased ILK expression, which is dependent on EP4 signaling and on induction of Sp1 protein and Sp1 DNA-binding activity in the ILK promoter. These studies suggest a novel molecular mechanism by which PGE₂ stimulates NSCLC cell growth and unveils a new molecular target for the development of therapies against NSCLC. [Cancer Res 2009;69(3):896–904]

This article has been cited by other articles:

				X. Sun, J. D. Ritzenthaler, X. Zhong, Y. Zheng, J. Roman, and S. Han Nicotine Stimulates PPAR{beta}/{delta} Expression in Human Lung Carcinoma Cells through Activation of PI3K/mTOR and Suppression of AP-2{alpha} Cancer Res., August 15, 2009; 69(16): 6445 - 6453. [Abstract] [Full Text] [PDF]